Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company conducted a study titled ‘The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT).’ The study aimed to evaluate the efficacy and safety of tirzepatide compared to dulaglutide in patients with type 2 diabetes who are at increased risk of cardiovascular events. This research is significant as it addresses the need for effective treatments in managing cardiovascular risks associated with diabetes.
Intervention/Treatment: The study tested two drugs: Tirzepatide and Dulaglutide. Both are administered subcutaneously once a week. Tirzepatide is the experimental drug, while Dulaglutide serves as the active comparator. The goal is to determine which drug better reduces cardiovascular events in the target population.
Study Design: This interventional study was designed as a Phase 3, randomized, parallel assignment with double masking involving both participants and investigators. The primary purpose was treatment-focused, aiming to compare the effects of the two drugs on cardiovascular outcomes.
Study Timeline: The study began on May 29, 2020, and was completed as of the last update on July 22, 2025. These dates are crucial as they indicate the study’s duration and the timeline for data collection and analysis.
Market Implications: The completion of this study could significantly influence Eli Lilly’s stock performance and investor sentiment, particularly if tirzepatide shows superior efficacy. This could position Eli Lilly favorably against competitors in the diabetes treatment market, potentially leading to increased market share and investor confidence.
The study is completed, with further details available on the ClinicalTrials portal.